Purchase this article with an account.
Delphine Lam, Christine Fardeau, Isabelle Koné-Paut, Isabelle Marie, Frederic Mouriaux, Veronique Despert, Michel Weber, Chloe Couret, Phuc Lehoang, Pierre Quartier, Bahram Bodaghi; Evolution of intraocular inflammation after the end of the ADJUVITE study. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3520. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the efficacy of adalimumab on uveitis and its tolerance, after the end of the ADJUVITE study.
Retrospective, descriptive study of patients who were enrolled in the ADJUVITE study at Pitié-Salpêtrière, Necker, Kremlin Bicetre , Rennes and Nantes hospitals and evaluation of intraocular inflammation by laser flare meter and Standardization of Uveitis Nomenclature criteria.
Twenty-six patients were included. Median age was 4.0 +/- 3.2 years. Mean follow-up time was 56.3 months (median 58.0 +/- 17.3; range 10-82). At the end of ADJUVITE study, mean visual acuity was 0.16 logMAR. At the last follow-up visit, mean visual acuity was 0.17 logMAR. Mean laser flare meter value was 46.8 photons/ms at the end of ADJUVITE study and 32.6 photons/ms at last follow-up visit. Twenty-three patients on adalimumab had good uveitis control.
Adalimumab was well tolerated and efficient in maintaining good uveitis control in Juvenile Idiopathic Arthritis- associated uveitis, when conventional immunosuppressors were not sufficient. Most of the children were dependent on adalimumab. Further investigations are needed to determine the rhythm of tapering and duration of therapy in these children.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.
This PDF is available to Subscribers Only